INHBA
Inhibin beta A chain
As of the edition of 20 October 2026, INHBA (inhibin beta A chain, UniProt P08476) has 2 drugs tested at it and 3 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08476
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 16
- Disease areas
- Lungs and airways; Blood and lymph; Heart and blood vessels; Bones, joints and muscles; Cancer; Inherited and neonatal; Immune system; Nutrition and metabolism
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sotatercept | Marketed | Phase 4 | Ends 2036 |
| Garetosmab | Marketed | Phase 3 | Ends 2038 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Regeneron | Route B |
The other 1 company at INHBA
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at INHBA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.